Everence Capital Management Inc Neurocrine Biosciences Inc Transaction History
Everence Capital Management Inc
- $1.54 Billion
- Q4 2024
A detailed history of Everence Capital Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Everence Capital Management Inc holds 3,490 shares of NBIX stock, worth $491,741. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,490Holding current value
$491,741% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
627Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.41 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$725 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$363 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$263 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...